📢 *News* We are thrilled to announce that Heather Preston, a healthcare investor and Oxford graduate, has joined as General Partner to Oxonian Ventures. Heather has over 20 years of biotech investing experience at NEA, JPMorgan Partners, TPG Biotech and Pivotal Bioventures. In addition, Heather has been a Board Member at more than 20 companies, including currently a non-executive director at Oxford Nanopore Technologies and Oxford Biomedica. Read more>> https://lnkd.in/gBngAsC6 Life science research and innovation is a strength of the University of Oxford. The addition of Heather to the all Oxford Alumni leadership team at Oxonian Ventures, provides valuable life science expertise to our existing and future life science portfolio companies as they scale up their ventures. Current Oxonian Ventures BioTech Portfolio Companies AOA Dx Granza Bio (YC W24) Ligo Biosciences ExcepGen Valink Therapeutics biotx.ai Probably Genetic
About us
Oxonian Ventures is the leading early-stage venture fund investing in Oxford alumni founded companies, using investment capital from Oxford alumni and affiliated institutions. With a portfolio of over 30+ companies Oxonian Ventures brings together Oxonian founders and investors to move ventures forward and elevate the visibility and reputation of Oxonian founded companies.
- Website
-
www.oxonianventures.com
External link for Oxonian Ventures
- Industry
- Financial Services
- Company size
- 2-10 employees
- Headquarters
- Palo Alto, California
- Type
- Privately Held
- Founded
- 2016
Locations
-
Primary
Get directions
Palo Alto, California 94301, US
Employees at Oxonian Ventures
-
Cameron Turner
GenAI | Data Science | Venture Capital | Angel Investing | AI | Machine Learning | SaaS | Enterprise Software | Board Member | Private Equity |…
-
Martin Lee
Leading a digital product studio | Focused on the intersection between design & technology.
-
Gregory Peter
Growth Enthusiast - Private Equity | M&A | Venture Investing | Business Development
-
Christine S. Li-AuYeung, CPA, MBA
Strategic Risk Manager | Venture Capitalist | Board Member | Empowering Organizations & Managing Risks for Transformative Growth
Updates
-
Ligo Biosciences is hiring for deep learning researchers and wet lab scientists to accelerate the development of new enzymes. If you are US or UK based - apply to jobs@ligo.bio! #enzymes #AI #deeplearning #innovation
We are hiring! If you warm intro us to someone we hire, we will pay you $5,000. Flexible start dates if you havent graduated! Nature has spent billions of years evolving enzymes as a method for efficient catalysis, but most industrially relevant chemical reactions are not found in nature. We are building generative models that learn from natural enzymes to design new-to-nature enzymes that enable efficient biocatalysis throughout the $6 trillion chemical industry. We are a team of 4 Oxford AI researchers and scientists who moved to San Francisco to start Ligo. We are looking to expand the team and excited to meet curious, smart, fun people looking for a new opportunity in AI for Science. We are in the UK for a few weeks recruiting for deep learning researchers and wet lab scientists - tag recommendations and warm intro via jobs@ligo.bio (you can recommend yourself!) For those who crave challenge and have a fire inside to build something special— join us. What we are looking for: - Intense curiosity and drive for learning - Technical background (Maths, Physics, CS, Engineering degrees or a stacked Github). - Background in deep learning is a plus / Background in wet lab is required (for wet lab roles) - Relocate to SF (We will sponsor your visas) Backed by A.Capital Ventures, SV Angel, Hawktail, Liquid 2 Ventures, Soma Capital, Y Combinator, Paul Graham, Apoorva Mehta, Oxford Seed Fund, Oxonian Ventures, and more.
-
-
🦄 Yet more good news... University of Oxford alumni are ranked the top UK source of US Unicorn founders. 🦄 🇺🇸 🇬🇧 https://lnkd.in/gFkUKnrM Please join us for an upcoming information session to learn more about opportunities to invest in early stage Oxonian founded companies via our Fund III - still open to new investors. https://lnkd.in/gskKx4Pe #unicorn #investing #entrepreneurship
Professor at Stanford | Bestselling Author | Innovation | Venture Capital & Private Equity
🌎 International universities behind US Unicorn Founders In our study of 531 US unicorns, we identified the universities where 1,263 of their founders studied. Interestingly, 266 of them (21%) completed their education at universities outside the US. In total, 74 non-US universities from various countries boast at least one unicorn founder as their alumni. Tel Aviv University leads with 16 unicorn founders. The University of Waterloo and Technion - Israel Institute of Technology follow closely, with 11 unicorn founders each. 9 founders graduated from the Indian Institute of Technology, Kharagpur. While the The Hebrew University of Jerusalem, University of Oxford, University of Toronto, McGill University, and the Indian Institute of Technology, Delhi, each have 8 unicorn founders among their alumni. Thank you to the Stanford University Graduate School of Business Venture Capital Initiative team for spearheading this research. #stanford #stanfordgsb #venturecapital #startups #privateequity #finance
-
-
🔥 We're excited to see recent investments in Oxford Innovation🔥 • GSK invests £50M in University of Oxford research in cancer prevention • Larry Ellison invests £130M through the Ellison Institute of Technology Oxford for a new Oxford campus investing in healthcare, food security and climate change. • New £200M Life and Mind building opening in 2025 • ... and more to come https://lnkd.in/eTgAXRdC 👏 At Oxonian Ventures we're feeling the buzz of interest ... 💡 Interested to learn more about investing in early-stage Oxonian founded companies? Join us for an infosession. Our Fund III is still open to new investors. https://lnkd.in/gk7KfxXb #oxfordinnovation #investing #entrepreneurship
-
**Portfolio Update** It's great to see our portfolio company Valink Therapeutics scaling up with additions to their Board as they advance their innovation in bispecific antibody-drug conjugates (bsADCs). Congratulations to CEO and Co-Founder Arne Scheu and team, for adding such a depth of talent and experience. #biotech #innovation #antibodies
Valink Therapeutics is pleased to announce the appointment of Martin Williams as Chair of our Board of Directors. Martin has more than 35 years of experience in the global biopharmaceutical business and has led multiple U.S. companies through strategic growth, partnerships and important regulatory, financial and drug development milestones. His expertise will be instrumental to Valink as we discover and develop bispecific antibody-drug conjugates (bsADCs) with the potential to transform the treatment of care and other diseases. Additionally we are excited to announce the formation of our Scientific Advisory Board, a group of internationally recognized experts who have been at the forefront of ADCs and bispecific innovation and development. Its members are: Sonia Quaratino, MD, PhD Marc Damelin, PhD Bob Lutz, PhD Antoine Awad Mihriban Tuna, PhD Alexey Lugovskoy, PhD Learn more about these accomplished drug developers who are helping us shape the future of ADCs: https://lnkd.in/eey8SunM
-
**Quantum Update** It's been a big week for quantum computing. First Google announces a breakthrough with their new quantum computing chip and now Conductor Quantum our latest Oxonian Ventures investment announces access to their ML models for quantum device calibration and characterization. Congrats to Brandon Severin and Joel Pendleton. #quantumcomputing #ML #innovation
Announcing the Conductor Models Playground Today, we’re excited to unveil our Models Playground—a space where users can seamlessly interact with our machine learning models designed for quantum device calibration and characterization. Dive in below. https://lnkd.in/dFurnAs9
-
-
👏 It's a day to celebrate for University of Oxford Alumni - we have an amazing new cohort of Venture Associates joining Oxonian Ventures to support our investment in early-stage ventures founded by Oxford Alumni - so much talent, energy and brain power 🧠 😯 We are an unabashedly Oxford Alumni-centric fund: ✅ Oxonian investors ✅ Oxonian founders ✅ Oxonian team Please join us in welcoming our new Venture Associates: Kay Makishi, Martin Lee, Ian Hsu, Catherine Kauffman, Nicholas Angelides, PhD, Alexandra Preston, Florian Groelly, PhD If you are an Oxford Alumni please give these Associates some 💙 and let us know your college in the comments. Interested to learn more about our Oxford Alumni Venture Fund please DM. We have 30+ University of Oxford colleges represented by our Associates, Investors and Founders: St Edmund Hall Keble College, Oxford Christ Church, Oxford Lincoln College, University of Oxford Kellogg College, University of Oxford St Cross College, Oxford St Antony's College, University of Oxford University College, Oxford Balliol College, University of Oxford Merton College, Oxford St John's College, Oxford St Hilda's College, University of Oxford Brasenose College, University of Oxford Exeter College, Oxford Oriel College, Oxford Hertford College, University of Oxford Lady Margaret Hall Magdalen College, University of Oxford Corpus Christi College, University of Oxford New College, Oxford Pembroke College Oxford St Hugh's College, Oxford Somerville College Linacre College, Oxford Wolfson College, Oxford Worcester College, Oxford Saïd Business School, University of Oxford EnSpire Oxford ... #oxforduniversity #innovation
-
-
👏 Portfolio News: Ligo Biosciences' work in reproducing DeepMind AlphaFold3 from pseudocode recognized in Nature Magazine and Science Magazine - congrats!! Can't wait to hear more from this talented team on their ground-breaking modeling of enzyme design.
Excited for Ligo Biosciences to be included in both Nature Magazine and Science Magazine in their recent articles on the release of DeepMind's AlphaFold3 code. Disappointing to see Nature fail to acknowledge that all teams who reproduced DeepMind's code (Ligo Biosciences, Chai Discovery, Baidu, Inc., ByteDance) found significant errors in the pseudocode which prevented training and compromised reproducibility. It should not become the norm to bend the rules for large corporations publishing in scientific journals. Academic publishing standards should be the same for everyone.
-
🌎 Oxonian Ventures Impact Report - Just Released - First Edition. TL:DR 📈 - 53% of our portfolio companies have a female founder - 63% of our portfolio companies report having women on their board - 72% of portfolio companies report having underrepresented board members Many thanks to Fleur Heyns, and the team at Proof for use of their Impact Intelligence Platform to gather information for this report. Also thanks to our portfolio companies for their positive contributions: AOA Dx, Bloom Labs, Kadeya, CNote, Proof, Forte, Deep Planet, PingThings, Avela, ExcepGen, Valink Therapeutics, biotx.ai, Mote, Louisa AI, The Beans, ... #impact #innovation #ventureinvesting #venturebuilding
-
Oxonian Ventures reposted this
Founder, General Partner, Oxonian Ventures | Board Member | GTM Advisor | Cybersecurity | Identity | AI | IoT | Robotics
📣 Exciting opportunity for University of Oxford Alumni interested in venture capital and learning about early stage investing. Oxonian Ventures is recruiting for a new class of Venture Associates. This is a great learning experience, with the opportunity to contribute to the building of our latest fund, expand skills and build your network. Our Associates have gone on to careers in VC. More details here>> https://lnkd.in/dPpNxqdz PS - can you name the college shown in this photo? #venturecapital #oxford #earlystageinvesting #alumni
-